A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 48 days later Oct 21, 2026 → Dec 8, 2026
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 21, 2026 to Dec 8, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 7 of 41 entries
    • Study description expanded, about 3 words
  2. 2 versions Re-verified since Jun 30, 2026, no change to tracked fieldsv8-v9
  3. Site details revised at 1 of 2 sitesv7
  4. 2 versions Re-verified since Mar 26, 2026, no change to tracked fieldsv5-v6
  5. Primary and study completion dates: Oct 14, 2026 to Oct 21, 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary and study completion dates: Oct 6, 2026 to Oct 14, 2026v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
729 trials monitored
See 62 trials at risk
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
Trial Details
NCT Number NCT07290283
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions
(from sponsor)		 Healthy Participants
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov